Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

• Status: Completed
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: All

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a world health issue during the last months, affecting mostly countries with a high metabolic risk, like Mexico. Patients with type 2 diabetes (T2D) have an increased risk of any kind of infection as well as an increased mortality risk. Hyperglycemia has been established as an important predictor of mortality in patients with T2D and SARS-CoV-2. The standard treatment of hyperglycemia in hospitalized patients has been basen on insulin schemes, but recently evidence suggest the utility of some other drugs, reducing the risk of hypoglucemia and increasing the probability of a proper metabolic control. The goal of this study is to compare the utility of dipeptidyl peptidase-4 inhibitor (DPP4i) as a combination with insulin on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 and hyperglycemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Regional de Alta Especialidad del Bajio
• Treatments: Insulin; Insulin, Globin Zinc; Linagliptin

Criteria

Inclusion Criteria:

• Hospitalized patients with confirmed infection by SARS-CoV-2

• Hyperglycemia higher than 140 mg/dl

• Patients accepting oral medications

• Both sex

• Older than 18 years of age

• Patients who accept to participate in the study and sign the consent form

Exclusion Criteria:

• Type 1 diabetes

• Pregnancy

• Hyperosmolar hyperglycemic state or diabetic ketoacidosis